JAADRCT
Randomized controlled study of nemolizumab in patients with chronic kidney disease-associated pruritus: NIKAIA-1.
ConclusionAlthough the primary endpoint was not met, the trial demonstrated a favorable safety profile and signals of reduced pruritus and improved itch-related quality of life in patients with chronic kidney disease-associated pruritus over 12 weeks.
Mathur VS, Fishbane S, … senior author Yosipovitch GJournal of the American Academy of Dermatology